SGAM
ALXN

Smith Group Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Smith Group Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24,510
Closed -$3.83M – 348
2020
Q4 		$3.83M Sell
24,510
-11,900
-33% -$1.53M 0.22% 72
2020
Q3 		$4.17M Sell
36,410
-60
-0.2% -$6.47K 0.22% 83
2020
Q2 		$4.09M Sell
36,470
-16,920
-32% -$1.8M 0.23% 83
2020
Q1 		$4.79M Sell
53,390
-2,270
-4% -$223K 0.26% 82
2019
Q4 		$6.02M Buy
+55,660
New +$5.95M 0.25% 84
2015
Q1 		– Sell
-87,877
Closed -$16.3M – 463
2014
Q4 		$16.3M Buy
87,877
+10
+0% +$1.85K 0.57% 67
2014
Q3 		$14.6M Buy
87,867
+567
+0.6% +$93.1K 0.54% 71
2014
Q2 		$13.6M Buy
+87,300
New +$13.8M 0.5% 73

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $4.65B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return